<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505102</url>
  </required_header>
  <id_info>
    <org_study_id>SAREFU123</org_study_id>
    <nct_id>NCT00505102</nct_id>
  </id_info>
  <brief_title>Safe Renal Function In Long Term Heart Transplanted Patients</brief_title>
  <acronym>SAREFU</acronym>
  <official_title>Efficacy and Safety of Everolimus to SAve REnal Function (SAREFU) in Long Term Heart Transplanted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify whether the reduction of cyclosporine dosages
      associated with Everolimus administration may improve renal function as compared to patients
      maintained on standard immunosuppressive therapy
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function Evaluated measuring Creatinine, Creatinine Clearance (MDRD and Cockcroft-Gault) and Urinary excretion of Protein, albumin and alpha-1-microglobulin</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality, infections, incidence of acute myocardial rejection, Heart Failure, Chronic Rejection, Mace</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>cyclosporine dose reduced of 50% after introduction of everolimus</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart Transplant patients with more than 1 year of follow-up

          -  Creatinine lower than 3.5 mg/dl

          -  GFR Higher than 20 ml/min (calculated with Cockcroft-Gault formula)

          -  Cyclosporine in maintenance immunosuppressive therapy

          -  Patient must be able to sign an approve informed consent

          -  Prior History of acute rejection within the last 3 months

          -  Females of childbearing age may be included if pregnancy is excluded and acceptable
             contraception measures are used

        Exclusion Criteria:

          -  Patients who are recipients of multiple organ transplants

          -  Prior or current use of sirolimus or everolimus

          -  History of acute rejection within the last 6 months

          -  Coronary Artery Bypass Surgery or other cardiac surgery in the past 3 months

          -  Patient not able to attend all follow-up evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Fiocchi, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Transplant Center Ospedali Riuniti Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Transplant Center Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Transplantad Center OspedaliRiuniti Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931-40.</citation>
    <PMID>12954741</PMID>
  </reference>
  <reference>
    <citation>Rothenburger M, Teerling E, Bruch C, Lehmkuhl H, Suwelack B, Bara C, Wichter T, Hinder F, Schmid C, Stypmann J. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant. 2007 Mar;26(3):250-7.</citation>
    <PMID>17346627</PMID>
  </reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>February 12, 2008</last_update_submitted>
  <last_update_submitted_qc>February 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Roberto Fiocchi</name_title>
    <organization>Ospedali Riuniti Bergamo</organization>
  </responsible_party>
  <keyword>Kidney Diseases</keyword>
  <keyword>Heart Transplantation</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Cyclosporine Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

